Halper Sadeh LLC said it is investigating the sale of Forte Biosciences, Inc. to argenx for $77.00 per share in cash, focusing on whether Forte and its board of directors complied with federal securities laws and fiduciary duties, including whether shareholders are receiving the best possible price, whether the sales process was fair and free of conflicts of interests, and whether all material information needed to evaluate the transaction was disclosed. The firm said insiders may receive substantial financial benefits not available to ordinary shareholders and that the proposed transaction may include terms limiting superior competing offers. Halper Sadeh said shareholders can discuss their rights and options at no cost or obligation, and that any matter would be handled on a contingent fee basis, with no out-of-pocket legal fees or expenses. It said it may seek increased consideration, additional disclosures, or other relief and benefits on behalf of shareholders.